Michael Zinda - May 17, 2021 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Role
EVP, Chief Science Officer
Signature
/s/ Steve Forte, Attorney-in-Fact
Stock symbol
RPTX
Transactions as of
May 17, 2021
Transactions value $
-$490,710
Form type
4
Date filed
5/18/2021, 05:53 PM
Next filing
Aug 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Stock Sale -$23.2K -732 -1.45% $31.65 49.8K May 17, 2021 Direct F1, F2
transaction RPTX Common Stock Sale -$407K -12.4K -24.98% $32.72 37.4K May 17, 2021 Direct F1, F3
transaction RPTX Common Stock Sale -$60.5K -1.83K -4.9% $33.07 35.5K May 17, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.03 to $33.01 inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.17 inclusive.